{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:22:55Z","timestamp":1782336175661,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peramivir offers a single\u2010dose intravenous (IV) treatment option for influenza (vs 5\u2010day oral dosing for oseltamivir). We sought to compare outcomes of emergency department (ED) patients at high risk for influenza complications treated with IV peramivir vs oral oseltamivir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      During the 2015\u201016 and 2016\u201017 influenza seasons, adult patients in two US EDs were randomized to either oral oseltamivir or IV peramivir treatment group. Eligibility included positive molecular influenza test; met CDC criteria for antiviral treatment; able to provide informed consent and agree to follow\u2010up assessment. Outcomes were measured by clinical end\u2010point indicators, including FLU\u2010PRO Score, Ordinal Scale, Patient Global Impression on Severity Score, and Karnofsky Performance Scale for 14\u00a0days. Non\u2010inferior\n                      <jats:italic>t<\/jats:italic>\n                      test was performed to assess comparative outcomes between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five hundred and seventy\u2010five (68%) of 847 influenza\u2010positive patients were approached. Two hundred and eighty\u2010four met enrollment criteria and 179 were enrolled; of these 95 (53%) were randomized to peramivir, and 84 to oseltamivir. Average FLU\u2010PRO score at baseline was similar (peramivir: 2.67 vs oseltamivir: 2.52); the score decreased over time for both groups (day 5: peramivir: 1.71 vs oseltamivir: 1.62; day 10: peramivir: 1.48 vs oseltamivir: 1.37; day 14: peramivir: 1.40 vs oseltamivir: 1.33; all\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.05 for significantly non\u2010inferior). Influenza\u2010related complications were similar between two groups (All: peramivir: 31% vs oseltamivir: 21%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&gt;\u00a0.05; pneumonia: peramivir: 11% vs oseltamivir: 14%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&gt;\u00a0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical outcomes of influenza\u2010infected patients treated with single\u2010dose IV peramivir were comparable to those treated with oral oseltamivir, suggesting potential utility of peramivir for influenza\u2010infected patients in the ED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/irv.12794","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T07:41:56Z","timestamp":1601624516000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intravenous peramivir vs oral oseltamivir in high\u2010risk emergency department patients with influenza: Results from a pilot randomized controlled study"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1616-8014","authenticated-orcid":false,"given":"Yu\u2010Hsiang","family":"Hsieh","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea F.","family":"Dugas","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"LoVecchio","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine University of Arizona College of Medicine Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breana","family":"McBryde","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin P.","family":"Ricketts","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Saliba\u2010Shaw","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Rothman","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA"},{"name":"Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Centers for Disease Control and Prevention (CDC).Disease Burden of Influenza.https:\/\/www.cdc.gov\/flu\/about\/disease\/burden.htm. Accessed February 13 2020."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy088"},{"key":"e_1_2_9_4_1","unstructured":"National Center for Immunization and Respiratory Diseases (NCIRD).Past Seasons Estimated Influenza Disease Burden.https:\/\/www.cdc.gov\/flu\/about\/disease\/burden.htm. Accessed February 13 2020."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.12111"},{"key":"e_1_2_9_6_1","unstructured":"RuiP KangK.National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables.https:\/\/www.cdc.gov\/nchs\/data\/nhamcs\/web_tables\/2015_ed_web_tables.pdf. Accessed December 11 2018."},{"issue":"1","key":"e_1_2_9_7_1","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza \u2013\u2010 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore A","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_9_8_1","unstructured":"National Center for Immunization and Respiratory Diseases (NCIRD).Influenza Antiviral Medications: Summary for Clinicians.https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary\u2010clinicians.htm. Accessed December 13 2018."},{"key":"e_1_2_9_9_1","unstructured":"National Center for Immunization and Respiratory Diseases (NCIRD).What You Should Know About Influenza (Flu) Antiviral Drugs.https:\/\/www.cdc.gov\/flu\/pdf\/freeresources\/updated\/antiviral\u2010factsheet\u2010updated.pdf. Accessed December 14 2018."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008945"},{"key":"e_1_2_9_11_1","unstructured":"U.S. Food and Drug Administration.FDA approves new drug to treat influenza.https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm624226.htm. Accessed December 14 2018."},{"issue":"3","key":"e_1_2_9_12_1","first-page":"337","article-title":"Baloxavir and treatment\u2010emergent resistance: public health insights and next steps","volume":"221","author":"Gubareva L","year":"2020","journal-title":"J Infect Dis"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2511.190757"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00360-11"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2874"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx129"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu632"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S86460"},{"issue":"3","key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"e0194180","DOI":"10.1371\/journal.pone.0194180","article-title":"Performance of the inFLUenza Patient\u2010Reported Outcome (FLU\u2010PRO) diary in patients with influenza\u2010like illness (ILI)","volume":"13","author":"Jr P","year":"2018","journal-title":"PLoS One"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctt1xp3vbc.10"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.379"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30174-1"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3113"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24373"},{"issue":"1563","key":"e_1_2_9_25_1","first-page":"1","article-title":"Antiviral drugs for treatment and prophylaxis of seasonal influenza","volume":"61","year":"2019","journal-title":"Med Lett Drugs Ther."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ptdy.2018.12.006"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2014.06.001"},{"key":"e_1_2_9_28_1","unstructured":"BrownT.EMA Panel Backs Zanamivir IV for Complicated Severe Influenza.https:\/\/www.medscape.com\/viewarticle\/909744. Accessed February 27 2020."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz171"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ146"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2018.01.030"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws299"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213972"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2010.09.028"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.12.1455"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/dmp.2014.156"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.12794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/irv.12794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.12794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T10:23:01Z","timestamp":1693650181000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.12794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/irv.12794"],"URL":"https:\/\/doi.org\/10.1111\/irv.12794","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/IRV.12794\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12794\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"2019-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}